Dr Reddy's launches drug for Parkinson's in US market

Announcement follows approval from USFDA

Dr Reddy's Laboratories Limited announced today that it has launched Pramipexole dihydrochloride extended-release tablets of 0.375 mg, 0.75 mg, 3 mg, 4.5 mg, in the US market on Tuesday, following the approval by the United States Food and Drug Administration (USFDA) .

The drug is a therapeutic equivalent generic version of Mirapex ER owned by Boehringer Ingelheim company. The product is used to treat symptoms of Parkinson's disease.

Mirapex ER brand and generic had US sales of approximately $ 48.3 million for the most recent twelve months ending in June, 2015, the company said quoting the IMS Health data.